Vascular endothelial growth factor and the kidney: Something of the marvellous

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 1, 2014, Pages 87-92

  Advani, Andrew ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

diabetes; podocyte; soluble fms like tyrosine kinase 1; vascular endothelial growth factor; vascular endothelial growth factor receptor 2

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NCK PROTEIN; NEPHRIN; PLATELET DERIVED GROWTH FACTOR B; PROTEIN KINASE C; SYNDECAN 1; SYNDECAN 4; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ACTIN FILAMENT; AUTOPHOSPHORYLATION; CELL ADHESION; DIABETIC NEPHROPATHY; GLOMERULUS; HETEROZYGOSITY; HUMAN; KIDNEY; MICROENVIRONMENT; PARACRINE SIGNALING; PODOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; AUTOCRINE COMMUNICATION; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84890568808     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000437329.41546.a9     Document Type: Review

References (50)

1. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111:707-716.
2. CooperME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48:2229-2239.
3. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380:439-442.
4. Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 2007; 58:491-504.
5. Keyt BA, Nguyen HV, Berleau LT, et al. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 1996; 271:5638-5646.
6. Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 2001; 276:26969-26979.
7. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 2001; 33:409-420
8. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-658.
9. Jin J, Sison K, Li C, et al. Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell 2012; 151:384-399. This groundbreaking study defines a novel autocrine role for podocyte-derived sFLT1 through binding to lipid microdomains and regulating actin rearrangements within the cell.
10. Bates DO, Cui TG, Doughty JM, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002; 62:4123-4131.
11. Rennel ES, Hamdollah-Zadeh MA, Wheatley ER, et al. Recombinant human VEGF165b protein is an effective anticancer agent in mice. Eur J Cancer 2008; 44:1883-1894.
12. Simon M, Grone HJ, Johren O, et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995; 268:F240-F250.
13. Kretzler M, Schroppel B, Merkle M, et al. Detection of multiple vascular endothelial growth factor splice isoforms in single glomerular podocytes. Kidney Int Suppl 1998; 67:S159-S161.
14. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129-1136.
15. Sison K, Eremina V, Baelde H, et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 2010; 21:1691-1701.
16. Veron D, Reidy KJ, Bertuccio C, et al. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int 2010; 77:989-999.
17. Oltean S, Neal CR, Mavrou A, et al. VEGF165b overexpression restores normal glomerular water permeability in VEGF164-overexpressing adult mice. Am J Physiol Renal Physiol 2012; 303:F1026-F1036. The effects of simultaneous overexpression of VEGF164 and VEGF165b.
18. Ma J, Matsusaka T, Yang HC, et al. Induction of podocyte-derived VEGF ameliorates podocyte injury and subsequent abnormal glomerular development caused by puromycin aminonucleoside. Pediatr Res 2011; 70:83-89.
19. Schumacher VA, Schlotzer-Schrehardt U, Karumanchi SA, et al. WT1-dependent sulfatase expression maintains the normal glomerular filtration barrier. J Am Soc Nephrol 2011; 22:1286-1296.
20. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006; 290:H560-H576.
21. Ku CH, White KE, Dei Cas A, et al. Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes 2008; 57:2824-2833
22. Mima A, Kitada M, Geraldes P, et al. Glomerular VEGF resistance induced by PKCdelta/SHP-1 activation and contribution to diabetic nephropathy. Faseb J 2012; 26:2963-2974. The effect of high glucose induced PKCd upregulation in preventing the podocyte response to VEGF-A.
23. Hohenstein B, Colin M, Foellmer C, et al. Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans. Nephrol Dial Transplant 2010; 25:3170-3180.
24. Tufro A, Veron D. VEGF and podocytes in diabetic nephropathy. Semin Nephrol 2012; 32:385-393. A review of the actions of VEGF in podocytes with a focus on autocrine effects.
25. Muller-Deile J, Worthmann K, Saleem M, et al. The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Physiol Renal Physiol 2009; 297:F1656-F1667.
26. Bertuccio C, Veron D, Aggarwal PK, et al. Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes. J Biol Chem 2011; 286:39933-39944.
27. Lenkkeri U, Mannikko M, McCready P, et al. Structure of the gene for congenital nephrotic syndrome of the Fnnish type (NPHS1) and characterization of mutations. Am J Hum Genet 1999; 64:51-61.
28. Veron D, Reidy K, Marlier A, et al. Induction of podocyte VEGF164 overexpression at different stages of development causes congenital nephrosis or steroid-resistant nephrotic syndrome. Am J Pathol 2010; 177:2225-2233.
29. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 2009; 15:1298-1306.
30. Bevan HS, van den Akker NM, Qiu Y, et al. The alternatively spliced antiangiogenic family of VEGF isoforms VEGFxxxb in human kidney development. Nephron Physiol 2008; 110:57-67.
31. Harper SJ, Bates DO. VEGF-A splicing: The key to antiangiogenic therapeutics Nat Rev Cancer 2008; 8:880-887.
32. Qiu Y, Ferguson J, Oltean S, et al. Overexpression of VEGF165b in podocytes reduces glomerular permeability. J Am Soc Nephrol 2010; 21:1498-1509.
33. Cha DR, Kang YS, Han SY, et al. Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J Endocrinol 2004; 183:183-194.
34. de Vriese AS, Tilton RG, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12:993-1000.
35. Sung SH, Ziyadeh FN, Wang A, et al. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006; 17:3093-3104.
36. Lindenmeyer MT, Kretzler M, Boucherot A, et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol 2007; 18:1765-1776.
37. Baelde HJ, Eikmans M, Lappin DW, et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 2007; 71:637-645.
38. Hohenstein B, Hausknecht B, Boehmer K, et al. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 2006; 69:1654-1661.
39. Grone HJ, Simon M, Grone EF. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. J Pathol 1995; 177:259-267.
40. Shulman K, Rosen S, Tognazzi K, et al. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 1996; 7:661-666.
41. Advani A, Gilbert RE. The endothelium in diabetic nephropathy. Semin Nephrol 2012; 32:199-207. A review of the role of endothelial injury in diabetic nephropathy with a focus on the VEGF paradox
42. Yuen DA, Stead BE, Zhang Y, et al. eNOS deficiency predisposes podocytes to injury in diabetes. J Am Soc Nephrol 2012; 23:1810-1823. This study reports the effects of VEGFR-2 blockade in diabetic wildtype and eNOS-/-mice and explores the pathomechanisms underlying albuminuria development in diabetic eNOS-/-mice.
43. Advani A, Kelly DJ, Advani SL, et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A 2007; 104:14448-14453.
44. Advani A, Connelly KA, Advani SL, et al. Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes. Biomed Res Int 2013; 2013:201475.
45. Veron D, Bertuccio CA, Marlier A, et al. Podocyte vascular endothelial growth factor (Vegf(1)(6)(4)) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia 2011; 54:1227-1241.
46. Sivaskandarajah GA, Jeansson M, Maezawa Y, et al. Vegfa protects the glomerular microvasculature in diabetes. Diabetes 2012; 61:2958-2966. This study reports an acceleration in glomerular injury with podocyte-specific VEGF-A deletion and diabetes induction.
47. Edelbauer M, Kshirsagar S, Riedl M, et al. Soluble VEGF receptor 1 promotes endothelial injury in children and adolescents with lupus nephritis. Pediatr Nephrol 2012; 27:793-800.
48. Lee AS, Lee JE, Jung YJ, et al. Vascular endothelial growth factor-C and-D are involved in lymphangiogenesis in mouse unilateral ureteral obstruction. Kidney Int 2013; 83:50-62.
49. Chade AR, Kelsen S. Reversal of renal dysfunction by targeted administration of VEGF into the stenotic kidney: A novel potential therapeutic approach. Am J Physiol Renal Physiol 2012; 302:F1342-F1350.
50. Veron D, Villegas G, Aggarwal PK, et al. Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus. PLoS One 2012; 7:e40589.